ZA942571B - 1,5 benzodiazepine derivatives - Google Patents

1,5 benzodiazepine derivatives

Info

Publication number
ZA942571B
ZA942571B ZA942571A ZA942571A ZA942571B ZA 942571 B ZA942571 B ZA 942571B ZA 942571 A ZA942571 A ZA 942571A ZA 942571 A ZA942571 A ZA 942571A ZA 942571 B ZA942571 B ZA 942571B
Authority
ZA
South Africa
Prior art keywords
benzodiazepine derivatives
benzodiazepine
derivatives
Prior art date
Application number
ZA942571A
Other languages
English (en)
Inventor
Harry Finch
Pritom Shah
Robin Arthur Ellis Carr
Original Assignee
Glaxo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Inc filed Critical Glaxo Inc
Publication of ZA942571B publication Critical patent/ZA942571B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0827Tripeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ZA942571A 1993-04-15 1994-04-14 1,5 benzodiazepine derivatives ZA942571B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939307833A GB9307833D0 (en) 1993-04-15 1993-04-15 Modulators of cholecystokinin and gastrin

Publications (1)

Publication Number Publication Date
ZA942571B true ZA942571B (en) 1994-11-11

Family

ID=10733915

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA942571A ZA942571B (en) 1993-04-15 1994-04-14 1,5 benzodiazepine derivatives
ZA942570A ZA942570B (en) 1993-04-15 1994-04-14 1,5 benzodiazepine derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA942570A ZA942570B (en) 1993-04-15 1994-04-14 1,5 benzodiazepine derivatives

Country Status (34)

Country Link
US (2) US5646140A (cs)
EP (1) EP0694039B1 (cs)
JP (1) JP3406317B2 (cs)
KR (1) KR100364948B1 (cs)
CN (1) CN1058487C (cs)
AP (2) AP462A (cs)
AT (1) ATE198894T1 (cs)
AU (1) AU681139B2 (cs)
CA (1) CA2158973C (cs)
CZ (1) CZ286695B6 (cs)
DE (1) DE69426624T2 (cs)
DK (1) DK0694039T3 (cs)
EC (1) ECSP941066A (cs)
ES (1) ES2154674T3 (cs)
FI (1) FI954853A (cs)
GB (1) GB9307833D0 (cs)
GR (1) GR3035641T3 (cs)
HK (1) HK1003943A1 (cs)
HU (1) HU223467B1 (cs)
IL (2) IL109316A (cs)
IS (2) IS4147A (cs)
MY (2) MY131569A (cs)
NO (1) NO311133B1 (cs)
NZ (1) NZ265272A (cs)
OA (1) OA10355A (cs)
PE (2) PE50594A1 (cs)
PH (1) PH30897A (cs)
PL (1) PL178790B1 (cs)
PT (1) PT694039E (cs)
RU (1) RU2135486C1 (cs)
SK (1) SK281211B6 (cs)
TW (1) TW487703B (cs)
WO (1) WO1994024149A1 (cs)
ZA (2) ZA942571B (cs)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE214056T1 (de) * 1993-12-28 2002-03-15 Shionogi & Co Benzodiazepinderivate
CA2186900A1 (en) * 1994-04-14 1995-10-26 Christopher Joseph Aquino Cck or gastrin modulating 5-heterocyclic-1,5-benzodiazepines
US5739129A (en) * 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
PE27497A1 (es) * 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
JPH09511998A (ja) * 1994-04-15 1997-12-02 グラクソ、ウェルカム、インコーポレーテッド 1,4 − ベンゾジアゼピン化合物を用いたコレシストキニンアゴニスト活性の誘導方法
GB9420747D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc 1,5 benzodiazepine derivatives
GB9420748D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc 1,5 benzodiazepine derivatives
GB9420763D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
US5780464A (en) * 1994-10-14 1998-07-14 Glaxo Wellcome Inc. Enteric coated compositions of 1,5-benzodiazepine derivatives having CCK antagonistic or agonistic activity
US5910495A (en) * 1994-10-14 1999-06-08 Glaxo Wellcome Inc. Use of 1,5-benzo b!1,4-diazepines to control gastric emptying
DE69637211T2 (de) 1995-12-11 2008-05-08 New England Medical Center Hospitals, Inc., Boston Test für und verwendungen von liganden von peptidhormonrezeptoren.
US5750353A (en) * 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
ATE248823T1 (de) * 1996-12-10 2003-09-15 Zeria Pharm Co Ltd 1,5-benzodiazepinderivate
GEP20022709B (en) 1997-04-15 2002-06-25 Csir Za Pharmaceutical Compositions Having Appetite Suppressant Activity
AR022044A1 (es) * 1999-05-06 2002-09-04 Glaxo Group Ltd Derivados de 1,5-benzodiazepina
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
US20020180095A1 (en) * 2001-05-29 2002-12-05 Berard Steven O. Thermally conductive carbon fiber extrusion compounder and method of using same
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
ES2319886T3 (es) * 2002-02-20 2009-05-14 Abbott Laboratories Compuestos azabiciclicos condensados que inhiben el sutipo 1 del receptor valinoide (vr1).
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
JP4069159B2 (ja) * 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ[e]アズレン誘導体及びそれらのアナログ
CN1333077C (zh) * 2005-04-15 2007-08-22 华南农业大学 缩胆囊素活性片段的串联表达及其应用
TW200824687A (en) * 2006-08-25 2008-06-16 Abbott Lab Compounds that inhibit TRPV1 and uses thereof
EP2134678A2 (en) * 2006-12-20 2009-12-23 Abbott Laboratories N-(5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain
CA2719018A1 (en) * 2008-03-20 2009-09-24 Abbott Laboratories Methods for making central nervous system agents that are trpv1 antagonists
CN103102285B (zh) * 2013-01-30 2015-07-29 淮阴师范学院 对氨基苯乙腈的制备方法
EP3071205B1 (en) 2013-11-18 2020-02-05 Forma Therapeutics, Inc. Benzopiperazine compositions as bet bromodomain inhibitors
RU2727169C2 (ru) 2013-11-18 2020-07-21 Форма Терапеутикс Инк. Композиции тетрагидрохинолинов в качестве ингибиторов бромодомена вет
RU2738232C2 (ru) 2015-07-22 2020-12-09 Энанта Фармасьютикалс, Инк. Производные бензодиазепина как ингибиторы rsv
WO2017136727A2 (en) 2016-02-05 2017-08-10 Denali Therapeutics Inc. Compounds, compositions and methods
ES2912295T3 (es) 2016-12-09 2022-05-25 Denali Therapeutics Inc Compuestos útiles como inhibidores de RIPK1
AU2018221820B2 (en) 2017-02-16 2023-11-02 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
WO2018226801A1 (en) * 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019067864A1 (en) 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
US10975094B2 (en) 2018-04-11 2021-04-13 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
US11254664B2 (en) 2019-03-18 2022-02-22 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as RSV inhibitors
US11179400B2 (en) 2019-04-09 2021-11-23 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
TW202334164A (zh) 2022-01-12 2023-09-01 美商戴納立製藥公司 (S)-5-苄基-N-(5-甲基-4-側氧基-2,3,4,5-四氫吡啶並[3,2-b][1,4]氧氮呯-3-基)-4H-1,2,4-三唑-3-甲醯胺的晶型

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2641280B1 (fr) * 1988-12-29 1994-01-21 Roussel Uclaf Nouveaux derives de la 2,4-dioxo 2,3,4,5-tetrahydro 1h-1,5-benzodiazepine, leur procede de preparation et leur application comme medicaments
FR2659653B1 (fr) * 1990-03-13 1992-05-22 Rhone Poulenc Sante Derives de l'uree, leur preparation et les medicaments les contenant.
US5206234A (en) * 1990-10-22 1993-04-27 Merck & Co., Inc. Benzolactam analogs as antagonists of cck
JP2904941B2 (ja) * 1991-01-28 1999-06-14 出光興産株式会社 スチレン系重合体の精製方法
GB9201180D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
CA2186900A1 (en) * 1994-04-14 1995-10-26 Christopher Joseph Aquino Cck or gastrin modulating 5-heterocyclic-1,5-benzodiazepines

Also Published As

Publication number Publication date
AU6567694A (en) 1994-11-08
CN1058487C (zh) 2000-11-15
MY112237A (en) 2001-05-31
HUT74102A (en) 1996-11-28
CA2158973C (en) 2006-06-06
PT694039E (pt) 2001-06-29
DE69426624T2 (de) 2001-06-21
NO954090L (no) 1995-12-13
HK1003943A1 (en) 1998-11-13
RU2135486C1 (ru) 1999-08-27
IL109316A (en) 1999-03-12
IL109316A0 (en) 1994-07-31
NO954090D0 (no) 1995-10-13
ATE198894T1 (de) 2001-02-15
WO1994024149A1 (en) 1994-10-27
ECSP941066A (es) 1994-11-16
NO311133B1 (no) 2001-10-15
CZ286695B6 (en) 2000-06-14
FI954853A0 (fi) 1995-10-12
PE50594A1 (es) 1995-01-06
AP462A (en) 1996-02-19
MY131569A (en) 2007-08-30
US5646140A (en) 1997-07-08
AP9400635A0 (en) 1994-04-30
TW487703B (en) 2002-05-21
SK281211B6 (sk) 2001-01-18
GB9307833D0 (en) 1993-06-02
OA10355A (en) 2001-10-19
IS4148A (is) 1994-10-16
IS4147A (is) 1994-10-16
AP512A (en) 1996-07-29
AU681139B2 (en) 1997-08-21
JP3406317B2 (ja) 2003-05-12
PL311084A1 (en) 1996-02-05
JPH08508744A (ja) 1996-09-17
PH30897A (en) 1997-12-23
SK125395A3 (en) 1996-06-05
KR100364948B1 (ko) 2003-03-29
ZA942570B (en) 1994-11-11
EP0694039A1 (en) 1996-01-31
DK0694039T3 (da) 2001-05-21
US5585376A (en) 1996-12-17
CZ267595A3 (en) 1996-04-17
DE69426624D1 (de) 2001-03-01
HU9502978D0 (en) 1995-12-28
CN1120843A (zh) 1996-04-17
PL178790B1 (pl) 2000-06-30
AP9400634A0 (en) 1994-04-30
PE50994A1 (es) 1995-01-06
GR3035641T3 (en) 2001-06-29
ES2154674T3 (es) 2001-04-16
NZ265272A (en) 1997-07-27
EP0694039B1 (en) 2001-01-24
FI954853A (fi) 1995-10-12
CA2158973A1 (en) 1994-10-27
IL109315A0 (en) 1994-07-31
HU223467B1 (hu) 2004-07-28

Similar Documents

Publication Publication Date Title
ZA942571B (en) 1,5 benzodiazepine derivatives
AP9300478A0 (en) 1,5 benzodiazepine derivatives
DE59403259D1 (en) Tetraaroxyperylen-3,4,9,10-tetracarbonsäurepolyimide
IL141908A0 (en) 1,4-benzodiazepine derivatives
GR3029455T3 (en) 3-Aryl-4-hydroxy-3-dihydrofuranone derivatives.
ZA941137B (en) Substitutet azolone derivatives.
AP9400657A0 (en) 1,5 benzodiazepine derivatives
AP9500731A0 (en) 1,5 benzodiazepine derivatives
GB2311779B (en) 2,3 benzodiazepine derivatives
ZA946569B (en) 1,5-Diphenyl-3-pyrazolylalkyl-N-hydroxydithiocarbamates
GB9317692D0 (en) Benzodiazepine derivatives
HU9301651D0 (en) Pyridyl-1,2,5-oxadiazole-carbonamide-2-oxide derivatives
HRP970162A2 (en) 1,25-dihydroxy-16,22,23-trisdehydro-cholecalciferol derivatives
GB2274282B (en) Piperazine-and piperidine-isoxazole derivatives
HU9403060D0 (en) 1,2,-dihydro-2-oxo-pyridines
IL110556A0 (en) 7 alpha-amino-1, 1-dioxocephem l- valylamides
GB9304440D0 (en) 2-acyloxycephem derivatives
HU9402902D0 (en) 1,2-dihydro-2-oxo-3-methyl-sulfonyl-aminomethyl-pyridine derivatives
EP0683787A1 (en) 4'-O-SULFONYL-ANTHRACYCLINE DERIVATIVES.
GB9406037D0 (en) 1,5 Benzodiazepine derivatives
ZA953056B (en) 1,5 benzodiazepine derivatives
ZA941763B (en) Carpaine derivatives.
HU9501251D0 (en) 17,20-epoxy-20-substituted-pregnane derivatives
GB9311613D0 (en) Thienylthiazole derivatives
GB9308013D0 (en) Benzodiazepine derivatives